| Objective 1.To explore the relationship between the expression of P53,P16 and WT-1 protein in ovarian serous carcinoma and clinical prognosis in patients with advanced serous carcinoma of ovary.2.To investigate the relationship between ascites tumor cells and clinical prognosis in patients with advanced ovarian serous carcinoma.3.To explore the relationship between serum tumor markers CA125,CA199 and HE4 and clinical prognosis.4.To explore the relationship between family history,age,clinical stage,lymph node metastasis and distant metastasis in patients with advanced ovarian serous carcinoma.5.To investigate the relationship between the pathological morphology,the number of pathological mitotic figures and the clinical prognosis of advanced ovarian serous carcinoma.Method 1.Pathological were divided into three groups by pathological examination.The pathological morphology of the patients was classified by microscope.There were solid,papillary and mixed type of HE,and the number of mitotic figures per 10 HPF was counted.2.Immunohistochemical staining S-P method was used to detect the expression of P53,P16 and WT-1 in 164 cases of advanced ovarian serous carcinoma.Age,family history,lymph node metastasis,distant metastasis and clinical sta ging of ascites tumor cells and the query registration 3.Age,family history,lymph node metastasis,distant metastasis and clinical staging of ascites tumor cells and the query registration medical record room,and record the numerical serological tumor markers CA125,CA199 and HE4 before and after the operation,every months of testing time.4.Of the 164 patients with advanced ovarian serous carcinoma were followed up by telephone.5.Statistical methods: using Graph Pad Prism 5 and SPSS 22 statistical softwarepackage for data analysis,multivariate analysis of variance analysis.The correlation analysis of the two levels of data using Pearson rank correlation analysis.Kaplan-Meier analysis and rank sum test were used to analyze the survival and relapse free survival,and the P value of <0.05 was statistically significant.Result 1.The relationship between the expression of P53,P16 and WT-1 protein in three patients with advanced ovarian serous carcinoma and its clinical prognosis.(1)There was no significant difference between P53 mutation and P53 nonsense mutation in P16 positive group and P16 negative group,WT-1 positive group and WT-1 negative group(P>0.05).(2)P53+P16+ group and P53-P16-group,P53+P16-group and P53-P16+ group,P53+WT-1+ group and P53-WT-1-group,P53+WT-1-group and P53-WT-1+ group,P16+WT-1+ group and P16-WT-1-group and clinical prognosis were not statistically significant(P>0.05).(3)There was significant difference between P16+WT-1-group and P16-WT-1+ group in clinical prognosis(P<0.05).The survival time of P16-WT-1+ patients is long,and the survival time of P16+WT-1-patients is short.(4)There was no significant difference between P53+P16+WT-1+ and P53-P16-WT-1-in clinical prognosis(P>0.05).2.The relationship between ascites tumor cells and clinical prognosis in patients with advanced ovarian serous carcinoma.There was a significant difference in tumor cells and clinical prognosis in patients with advanced ovarian serous carcinoma(P<0.05).Among them,the pati ents with ascites tumor cells were negative and the survival time was shorter.3.The relationship between serum tumor markers CA125,CA199 and HE4 and clinical prognosis.(1)There was no significant difference between preoperative and postoperative CA125,CA199 and HE4 in serum tumor markers(P>0.05).(2)The mean value of CA125 was significantly higher in the patients who died from 3-7 months after operation,and the difference was statistically significant(P<0.05).(3)The mean value of CA199 was higher in the third months after the operation,andthe difference was statistically significant(P<0.05).(4)The mean value of HE4 was significantly higher in the patients who died from 1-4 months after operation,and the difference was statistically significant(P<0.05).4.Relationship between family history,age,clinical stage,lymph node metastasis,distant metastasis and clinical prognosis in patients with advanced ovarian serous carcinoma.There was no significant difference in the family history,age,clinical stage,lymph node metastasis and distant metastasis in patients with advanced ovarian serous carcinoma(P>0.05).5.The relationship between the pathological morphology,the number of pathological mitotic figures and clinical prognosis in advanced ovarian serous carcinoma.(1)There was no significant difference in the pathological morphology and clinical prognosis of advanced ovarian serous carcinoma(P>0.05).(2)There was no significant difference in the number of pathological mitotic figures and clinical prognosis in advanced ovarian serous carcinoma(P>0.05).Conclusion 1.P16+WT-1-group and P16-WT-1+ group with clinical prognosis with statistical difference(P<0.05 P16-WT-1+),high survival rate,the survival rate of P16+WT-1-is low,the reliability of our future studies need to expand the sample size of the two groups were further verified the results,and the mechanism was analyzed;but the results of this study may for our further study molecular prognosis of ovarian high-grade serous carcinoma type based on.2.There was a significant difference between the ascites tumor cells and clinical prognosis in patients with advanced ovarian serous carcinoma(P<0.05).Among the patients with ascites tumor cell negative long-term survival and positive short survival(no ascites tumor cell survival.The standard deviation is 81.297 + 4.537,with ascites tumor cell survival.The standard deviation is 53.06 + 2.238).3.There was a statistical significance(P< 0.05)for distant metastases and clinical outcomes in patients with high levels of ovarial serous carcinoma.Patients with distant metastases have a short life span,and there are no distant metastases.4.From third to seventh months after surgery,postoperative death in patients serum tumor marker CA125 was higher than thesurvival group(P<0.05),deaths in patients with serological tumor markers CA125 mean in 33.86 + 19.25 ~ 95.80 + 75.18,and the survival group serological tumor marker CA125 in the mean 8.907 + 0.7028 to 14.47 + 1.683 CA125,after 3 months later if still in the above 50U/ml often indicates poor prognosis,and can be used as a prognostic indicator slightly late after operation.The mean value of serum tumor marker HE4 in the death group was significantly higher than that in the survival group(P<0.05)after 1-4 months.1-4 months in death group serum tumor marker HE4 value is from 113 + 40.17 to 137.8 + 56.02 after operation,and the survival group serological tumor marker HE4 value is from 56.39 + 3.022 to 66.86 + 4.489,HE4 in 1 months after operation in the later if the above 115U/ml indicates the clinical prognosis is poor,and can be used as early monitoring indicators of prognosis after surgery.Serological tumor marker CA199 third months after operation of serologic death cases were higher than that of survival cases,although the difference was statistically significant(P<0.05),but the difference was not significant,so the lack of clinical significance. |
PDF Full Text Request